Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaboration with GA2LEN)

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 61, Issue 9, 2006, Pages 1086-1096

  Bousquet, J ^a,an,ao   Van Cauwenberge, P ^b,an   Ait Khaled N ^c   Bachert, C ^d,an   Baena Cagnani, C E ^e   Bouchard, J ^f   Bunnag, C ^g   Canonica, G W ^h   Carlsen, K H ^i,an   Chen, Y Z ^j   Cruz, A A ^k   Custovic, A ^l   Demoly, P ^a   Dubakiene, R ^m   Durham, S ^n,an   Fokkens, W ^o,an   Howarth, P ^p,an   Kemp, J ^q   Kowalski, M L ^r,an   Kvedariene, V ^m   Lipworth, B ^s   Lockey, R ^t   Lund, V ^u   Mavale Manuel, S ^v   Meltzer, E O ^w   Mullol, J ^x,an   Naclerio, R ^y   Nekam, K ^z   Ohta, K ^aa   Papadopoulos, N ^ab,an   Passalacqua, G ^h   Pawankar, R ^ac   Popov, T ^ad   Potter, P ^ae   Price, D ^af   Scadding, G ^ag   Simons, F E R ^ah   Spicak, V ^ai   Valovirta, E ^aj   Wang, D Y ^ak   Yawn, B ^al   Yusuf, O ^am   more..

^a INSERM   (France)

^b GHENT UNIVERSITY   (Belgium)

^c The Union   (France)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

^e UNIVERSITY OF CÓRDOBA   (Spain)

^f ST JOSEPH S HOSPITAL   (Canada)

^g MAHIDOL UNIVERSITY   (Thailand)

^h UNIVERSITY OF GENOA   (Italy)

ⁱ UNIVERSITY OF OSLO   (Norway)

^j CAPITAL INSTITUTE OF PEDIATRICS   (China)

^k FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^l UNIVERSITY OF MANCHESTER   (United Kingdom)

^m VILNIUS UNIVERSITY   (Lithuania)

ⁿ ROYAL BROMPTON HOSPITAL   (United Kingdom)

^o UNIVERSITY OF AMSTERDAM   (Netherlands)

^p UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^q Lodz University ^*

^r UNIVERSITY OF LODZ   (Poland)

^s UNIVERSITY OF DUNDEE   (United Kingdom)

^t UNIVERSITY OF SOUTH FLORIDA   (United States)

^u UNIVERSITY COLLEGE LONDON   (United Kingdom)

^v University of Maputo   (Mozambique)

^w ALLERGY AND ASTHMA MEDICAL GROUP AND RESEARCH CENTER   (United States)

^x HOSPITAL CLÍNIC   (Spain)

^y UNIVERSITY OF CHICAGO   (United States)

^z Polyclinic of the Hospitaller Brothers   (Hungary)

^aa TEIKYO UNIVERSITY   (Japan)

^ab UNIVERSITY OF ATHENS   (Greece)

^ac NIPPON MEDICAL SCHOOL   (Japan)

^ad MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^ae UNIVERSITY OF CAPE TOWN   (South Africa)

^af UNIVERSITY OF ABERDEEN   (United Kingdom)

^ag Royal National TNE Hospital   (United Kingdom)

^ah UNIVERSITY OF MANITOBA   (Canada)

^ai Turku Allergy Center   (Czech Republic)

^aj Turku Allergy Center   (Finland)

^ak NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^al UNIVERSITY OF MINNESOTA   (United States)

^am GA2LEN   (Pakistan)

^an GA2LEN   (Belgium)

^ao HÔPITAL ARNAUD DE VILLENEUVE   (France)

more..

Author keywords

ARIA; Asthma; IgE; Pharmacotherapy; Rhinitis

Indexed keywords

ANTIHISTAMINIC AGENT; AZELASTINE; BECLOMETASONE; BUDESONIDE; CETIRIZINE; CHLORPHENIRAMINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLEMASTINE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DECONGESTIVE AGENT; DESLORATADINE; DIPHENHYDRAMINE; EBASTINE; EMEDASTINE; FEXOFENADINE; FLUTICASONE; HISTAMINE H1 RECEPTOR ANTAGONIST; IMMUNOGLOBULIN E; IPRATROPIUM BROMIDE; KETOTIFEN; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LEVOCETIRIZINE; LORATADINE; MIZOLASTINE; MOMETASONE FUROATE; MONTELUKAST; OLOPATADINE; OMALIZUMAB; UNINDEXED DRUG;

ALLERGIC CONJUNCTIVITIS; ALLERGIC RHINITIS; CARDIOTOXICITY; CLINICAL TRIAL; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG SAFETY; EMBASE; EVIDENCE BASED MEDICINE; GROWTH DISORDER; HUMAN; MEDLINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SOMNOLENCE; SYMPTOM;

EID: 33746785057     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2006.01144.x     Document Type: Review

References (133)

1. Bousquet J, Lockey R, Malling H. WHO Position Paper. Allergen immunotherapy: therapeuticvaccines for allergic diseases. Allergy 1998;53(Suppl. 54):1-55.
2. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108(Suppl. 5):S147-S334.
3. ARIA in the pharmacy: management of allergic rhinitis symptoms in the pharmacy. Allergic rhinitis and its impact on asthma. Allergy 2004;59:373-387.
4. Marinker M. From compliance to accordance: achieving shared goals in medicine taking. Report of the Royal Pharmaceutical of Great Britain Working party, 1998.
5. Bousquet J, Lund VJ, Van Cauwenberge P, Bremard-Oury C, Mounedji N, Stevens MT et al. Implementation of guidelines for seasonal allergic rhinitis: a randomized controlled trial. Allergy 2003;58:733-741.
6. Horak F, Stubner UP, Zieglmayer R, Harris AG. Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. J Allergy Clin Immunol 2002;109:956-961.
7. Horak F, Stubner P, Zieglmayer R, Kavina A, De Vos C, Burtin B et al. Controlled comparison of the efficacy and safety of cetirizine 10 mg o.d. and fexofenadine 120 mg o.d. in reducing symptoms of seasonal allergic rhinitis. Int Arch Allergy Immunol 2001;125:73-79.
8. Horak F, Stubner P, Zieglmeyer R, Harris AG. Comparison of the effects of desloratadine 5-mg daily and placebo on nasal airflow and seasonal allergic rhinitis symptoms induced by grass pollen exposure. Allergy 2003;58:481-485.
9. Deruaz C, Leimgruber A, Berney M, Pradervand E, Spertini F. Levocetirizine better protects than desloratadine in a nasal provocation with allergen. J Allergy Clin Immunol 2004;113:669-676.
10. Day JH, Briscoe MP, Rafeiro E, Ratz JD. Comparative clinical efficacy, onset and duration of action of levocetirizine and desloratadine for symptoms of seasonal allergic rhinitis in subjects evaluated in the Environmental Exposure Unit (EEU). Int J Clin Pract 2004;58:109-118.
11. Day JH, Briscoe MP, Rafeiro E, Hewlett D Jr, Chapman D, Kramer B. Randomized double-blind comparison of cetirizine and fexofenadine after pollen challenge in the Environmental Exposure Unit: duration of effect in subjects with seasonal allergic rhinitis. Allergy Asthma Proc 2004;25:59-68.
12. Perry TT, Corren J, Philip G, Kim EH, Conover-Walker MK, Malice MP et al. Protective effect of montelukast on lower and upper respiratory tract responses to short-term cat allergen exposure. Ann Allergy Asthma Immunol 2004;93:431-438.
13. Stubner P, Zieglmayer R, Horak F. A direct comparison of the efficacy of antihistamines in SAR and PAR: randomised, placebo-controlled studies with levocetirizine and loratadine using an environmental exposure unit - the Vienna Challenge Chamber (VCC). Curr Med Res Opin 2004;20:891-902.
14. Wilson A, Dempsey OJ, Sims EJ, Coutie WJ, Paterson MC, Lipworth BJ. Evaluation of treatment response in patients with seasonal allergic rhinitis using domiciliary nasal peak inspiratory flow. Clin Exp Allergy 2000;30:833-838.
15. Wilson AM, Sims EJ, Orr LC, Coutie WJ, White PS, Gardiner Q et al. Effects of topical corticosteroid and combined mediator blockade on domiciliary and laboratory measurements of nasal function in seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2001;87:344-349.
16. Wilson AM, Orr LC, Sims EJ, Lipworth BJ. Effects of monotherapy with intranasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis. Clin Exp Allergy 2001;31:61-68.
17. Wilson AM, Orr LC, Coutie WJ, Sims EJ, Lipworth BJ. A comparison of once daily fexofenadine versus the combination of montelukast plus loratadine on domiciliary nasal peak flow and symptoms in seasonal allergic rhinitis. Clin Exp Allergy 2002;32:126-132.
18. Lee DK, Gardiner M, Haggart K, Fujihara S, Lipworth BJ. Comparative effects of desloratadine, fexofenadine, and levocetirizine on nasal adenosine monophosphate challenge in patients with perennial allergic rhinitis. Clin Exp Allergy 2004;34:650-653.
19. Lee DK, Jackson CM, Soutar PC, Fardon TC, Lipworth BJ. Effects of single or combined histamine H1-receptor and leukotriene CysLT1-receptor antagonism on nasal adenosine monophosphate challenge in persistent allergic rhinitis. Br J Clin Pharmacol 2004;57:714-719.
20. Bender BG, Berning S, Dudden R, Milgrom H, Tran ZV. Sedation and performance impairment of diphenhydramine and second-generation antihistamines: a meta-analysis. J Allergy Clin Immunol 2003;111:770-776.
21. Meltzer EO, Charous BL, Busse WW, Zinreich SJ, Lorber RR, Danzig MR. Added relief in the treatment of acute recurrent sinusitis with adjunctive mometasone furoate nasal spray. The Nasonex Sinusitis Group. J Allergy Clin Immunol 2000;106:630-637.
22. Keith P, Nieminen J, Hollingworth K, Dolovich J. Efficacy and tolerability of fluticasone propionate nasal drops 400 μg once daily compared withlacebo for the treatment of bilateral polyposis in adults. Clin Exp Allergy 2000;30:1460-1468.
23. Penttila M, Poulsen P, Hollingworth K, Holmstrom M. Dose-related efficacy and tolerability of fluticasone propionate nasal drops 400 μg once daily and twice daily in the treatment of bilateral nasal polyposis: a placebo-controlled randomized study in adult patients. Clin Exp Allergy 2000;30:94-102.
24. Parikh A, Scadding GK, Darby Y, Baker RC. Topical corticosteroids in chronic rhinosinusitis: a randomized, double-blind, placebo-controlled trial using fluticasone propionate aqueous nasal spray. Rhinology 2001;39:75-79.
25. Dolor RJ, Witsell DL, Hellkamp AS, Williams JW Jr, Califf RM, Simel DL. Comparison of cefuroxime with or without intranasal fluticasone for the treatment of rhinosinusitis. The CAFFS Trial: a randomized controlled trial. Jama 2001;286:3097-3105.
26. Lavigne F, Cameron L, Renzi PM, Planet JF, Christodoulopoulos P, Lamkioued B et al. Intrasinus administration of topical budesonide to allergic patients with chronic rhinosinusitis following surgery. Laryngoscope 2002;112:858-864.
27. Bucher HC, Tschudi P, Young J, Periat P, Welge-Luussen A, Zust H et al. Effect of amoxicillin-clavulanate in clinically diagnosed acute rhinosinusitis: a placebo-controlled, double-blind, randomized trial in general practice. Arch Intern Med 2003;163:1793-1798.
28. Lund VJ, Black JH, Szabo LZ, Schrewelius C, Akerlund A. Efficacy and tolerability of budesonide aqueous nasal spray in chronic rhinosinusitis patients. Rhinology 2004;42:57-62.
29. Kiely JL, Nolan P, McNicholas WT. Intranasal corticosteroid therapy for obstructive sleep apnoea in patients with co-existing rhinitis. Thorax 2004;59:50-55.
30. Mansfield LE, Diaz G, Posey CR, Flores-Neder J. Sleep disordered breathing and daytime quality of life in children with allergic rhinitis during treatment with intranasal budesonide. Ann Allergy Asthma Immunol 2004;92:240-244.
31. Leurs R, Church MK, Taglialatela M. H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy 2002;32:489-498.
32. Bousquet J, Van-Cauwenberge P, Bachert C, Canonica G, Demoly P, Durham S et al. Requirements for medications commonly used in the treatment of allergic rhinitis. Allergy 2003;58:192-197.
33. Passalacqua G, Canonica GW, Bousquet J. Structure and classification of H1-antihistamines and overview of their activities. Clin Allergy Immunol 2002;17:65-100.
34. Simons FE. Advances in H1-antihistamines. N Engl J Med 2004;351:2207-2217.
35. Bousquet J, Van Cauwenberge P, Bachert C, Canonica GW, Demoly P, Durham SR et al. Requirements for medications commonly used in the treatment of allergic rhinitis. European Academy of Allergy and Clinical Immunology (EAACI), Allergic Rhinitis and its Impact on Asthma (ARIA). Allergy 2003;58:192-197.
36. Sullivan PW, Nichol MB. The economic impact of payer policies after the Rx-to-OTC switch of second-generation antihistamines. Value Health 2004;7:402-412.
37. Goldman DP, Joyce GF, Escarce JJ, Pace JE, Solomon MD, Laouri M et al. Pharmacy benefits and the use of drugs by the chronically ill. Jama 2004;291:2344-2350.
38. Murray JJ, Nathan RA, Bronsky EA, Olufade AO, Chapman D, Kramer B. Comprehensive evaluation of cetirizine in the management of seasonal allergic rhinitis: impact on symptoms, quality of life, productivity, and activity impairment. Allergy Asthma Proc 2002;23:391-398.
39. Ciprandi G, Tosca M, Passalacqua G, Canonica GW. Long-term cetirizine treatment reduces allergic symptoms and drug prescriptions in children with mite allergy. Ann Allergy Asthma Immunol 2001;87:222-226.
40. Simons FE, Silas P, Portnoy JM, Catuogno J, Chapman D, Olufade AO et al. Safety of cetirizine in infants 6 to 11 months of age: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol 2003;111:1244-1248.
41. Stevenson J, Cornah D, Evrard P, Vanderheyden V, Billard C, Bax M et al. Long-term evaluation of the impact of the h1-receptor antagonist cetirizine on the behavioral, cognitive, and psychomotor development of very young children with atopic dermatitis. Pediatr Res 2002;52:251-257.
42. Ng KH, Chong D, Wong CK, Ong HT, Lee CY, Lee BW et al. Central nervous system side effects of first- and second-generation antihistamines in school children with perennial allergic rhinitis: a randomized, double-blind, placebo-controlled comparative study. Pediatrics 2004;113:e116-e121.
43. Warner JO. A double-blinded, randomized, placebo-controlled trial of cetirizine in preventing the onset of asthma in children with atopic dermatitis: 18 months treatment and 18 months posttreatment follow-up. J Allergy Clin Immunol 2001;108:929-937.
44. Salmun LM, Lorber R. 24-hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis. BMC Fam Pract 2002;3:14.
45. Wilson AM, Haggart K, Sims EJ, Lipworth BJ. Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis. Clin Exp Allergy 2002;32:1504-1509.
46. Nayak AS, Schenkel E. Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. Allergy 2001;56:1077-1080.
47. Simons FE, Prenner BM, Finn A Jr. Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. J Allergy Clin Immunol 2003;111:617-622.
48. Berger WE, Schenkel EJ, Mansfield LE. Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion. Ann Allergy Asthma Immunol 2002;89:485-491.
49. Baena-Cagnani CE, Berger WE, Dubuske LM, Gurne SE, Stryszak P, Lorber R et al. Comparative effects of desloratadine versus montelukast on asthma symptoms and use of beta 2-agonists in patients with seasonal allergic rhinitis and asthma. Int Arch Allergy Immunol 2003;130:307-313.
50. Nicholson AN, Handford AD, Turner C, Stone BM. Studies on performance and sleepiness with the H1-antihistamine, desloratadine. Aviat Space Environ Med 2003;74:809-815.
51. Vuurman EF, Rikken GH, Muntjewerff ND, De Halleux F, Ramaekers JG. Effects of desloratadine, diphenhydramine, and placebo on driving performance and psychomotor performance measurements. Eur J Clin Pharmacol 2004;60:307-313.
52. Banfield C, Herron J, Keung A, Padhi D, Affrime M. Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole. Clin Pharmacokinet 2002;41(Suppl. 1):37-44.
53. Banfield C, Hunt T, Reyderman L, Statkevich P, Padhi D, Affrime M. Lack of clinically relevant interaction between desloratadine and erythromycin. Clin Pharmacokinet 2002;41(Suppl. 1):29-35.
54. Gupta S, Banfield C, Kantesaria B, Marino M, Clement R, Affrime M et al. Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study. Clin Ther 2001;23:451-466.
55. Ratner PH, Lim JC, Georges GC. Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis. The Ebastine Study Group. J Allergy Clin Immunol 2000;105(6 Pt 1):1101-1107.
56. Hampel F Jr, Howland W III, Van Bavel J, Ratner P. A randomized, double-blind, placebo-controlled study comparing the efficacy and safety of ebastine (20 and 10 mg) to loratadine 10 mg once daily in the treatment of seasonal allergic rhinitis. J Investig Allergol Clin Immunol 2004;14:56-63.
57. Ratner P, Hampel F Jr, Van Bavel J, Howland W III. Efficacy and safety of ebastine 20 mg compared to loratadine 10 mg once daily in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled study. Int Arch Allergy Immunol 2004;133:371-379.
58. Hindmarch I, Shamsi Z. The effects of single and repeated administration of ebastine on cognition and psychomotor performance in comparison to triprolidine and placebo in healthy volunteers. Curr Med Res Opin 2001;17:273-281.
59. Tagawa M, Kano M, Okamura N, Higuchi M, Matsuda M, Mizuki Y et al. Differential cognitive effects of ebastine and (+)-chlorpheniramine in healthy subjects: correlation between cognitive impairment and plasma drug concentration. Br J Clin Pharmacol 2002;53:296-304.
60. Gillen MS, Miller B, Chaikin P, Morganroth J. Effects of supratherapeutic doses of ebastine and terfenadine on the QT interval. Br J Clin Pharmacol 2001;52:201-204.
61. Frank H Jr, Gillen M, Rohatagi SS, Lim J, George G. A double-blind, placebo-controlled study of the efficacy and safety of ebastine 20 mg once daily given with and without food in the treatment of seasonal allergic rhinitis. J Clin Pharmacol 2002;42:1097-1104.
62. Van Cauwenberge P, Juniper EF. Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clin Exp Allergy 2000;30:891-899.
63. Potter PC, Schepers JM, Van Niekerk CH. The effects of fexofenadine on reaction time, decision-making, and driver behavior. Ann Allergy Asthma Immunol 2003;91:177-181.
64. Wahn U, Meltzer EO, Finn AF Jr, Kowalski ML, Decosta P, Hedlin G et al. Fexofenadine is efficacious and safe in children (aged 6-11 years) with seasonal allergic rhinitis. J Allergy Clin Immunol 2003;111:763-769.
65. Meltzer EO, Scheinmann P, Rosado Pinto JE, Bachert C, Hedlin G, Wahn U et al. Safety and efficacy of oral fexofenadine in children with seasonal allergic rhinitis - a pooled analysis of three studies. Pediatr Allergy Immunol 2004;15:253-260.
66. Horak F, Stubner P, Zieglmayer R, Kavina A, Corrado ME, Assandri A et al. Clinical study of the therapeutic efficacy and safety of emedastine difumarate versus cetirizine in the treatment of seasonal allergic rhinitis. Arzneimittelforschung 2004;54:666-672.
67. Leynadier F, Mees K, Arendt C, Pinelli ME. Efficacy and safety of levocetirizine in seasonal allergic rhinitis. Acta Otorhinolaryngol Belg 2001;55:305-312.
68. Potter PC. Levocetirizine is effective for symptom relief including nasal congestion in adolescent and adult (PAR) sensitized to house dust mites. Allergy 2003;58:893-899.
69. Bachert C, Bousquet J, Canonica GW, Durham SR, Klimek L, Mullol J et al. Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol 2004;114:838-844.
70. Gandon JM, Allain H. Lack of effect of single and repeated doses of levocetirizine, a new antihistamine drug, on cognitive and psychomotor functions in healthy volunteers. Br J Clin Pharmacol 2002;54:51-58.
71. Hindmarch I, Johnson S, Meadows R, Kirkpatrick T, Shamsi Z. The acute and sub-chronic effects of levocetirizine, cetirizine, loratadine, promethazine and placebo on cognitive function, psychomotor performance, and weal and flare. Curr Med Res Opin 2001;17:241-255.
72. Verster JC, Volkerts ER, Van Oosterwijck AW, Aarab M, Bijtjes SI, De Weert AM et al. Acute and subchronic effects of levocetirizine and diphenhydramine on memory functioning, psychomotor performance, and mood. J Allergy Clin Immunol 2003;111:623-627.
73. Verster JC, De Weert AM, Bijtjes SI, Aarab M, Van Oosterwijck AW, Eijken EJ et al. Driving ability after acute and sub-chronic administration of levocetirizine and diphenhydramine: a randomized, double-blind, placebo-controlled trial. Psychopharmacology (Berl) 2003;169:84-90.
74. Yang YH, Lin YT, Lu MY, Tsai MJ, Chiang BL. A double-blind, placebo-controlled, and randomized study of loratadine (Clarityne) syrup for the treatment of allergic rhinitis in children aged 3 to 12 years. Asian Pac J Allergy Immunol 2001;19:171-175.
75. Salmun LM, Herron JM, Banfield C, Padhi D, Lorber R, Affrime MB. The pharmacokinetics, electrocardiographic effects, and tolerability of loratadine syrup in children aged 2 to 5 years. Clin Ther 2000;22:613-621.
76. Bender BG, McCormick DR, Milgrom H. Children's school performance is not impaired by short-term administration of diphenhydramine or loratadine. J Pediatr 2001;138:656-660.
77. Vuurman EF, Van-Veggel LM, Uiterwijk MM, Leutner D, O'Hanlon JF. Seasonal allergic rhinitis and antihistamine effects on children's learning. Ann Allergy 1993;71:121-126.
78. Freche C, Leynadier F, Horak F, Hide D, Gracia FD, Goos M et al. Mizolastine provides effective symptom relief in patients suffering from perennial allergic rhinitis: a double-blind, placebo-controlled study versus loratadine. Ann Allergy Asthma Immunol 2002;89:304-310.
79. Guadano EM, Serra-Batlles J, Meseguer J, Castillo JA, De Molina M, Valero A et al. Rupatadine 10 mg and ebastine 10 mg in seasonal allergic rhinitis: a comparison study. Allergy 2004;59:766-771.
80. Berger WE, White MV. Efficacy of azelastine nasal spray in patients with an unsatisfactory response to loratadine. Ann Allergy Asthma Immunol 2003;91:205-211.
81. Laforce CF, Corren J, Wheeler WJ, Berger WE. Efficacy of azelastine nasal spray in seasonal allergic rhinitis patients who remain symptomatic after treatment with fexofenadine. Ann Allergy Asthma Immunol 2004;93:154-159.
82. Abelson MB, Turner D. A randomized, double-blind, parallel-group comparison of olopatadine 0.1% ophthalmic solution versus placebo for controlling the signs and symptoms of seasonal allergic conjunctivitis and rhinoconjunctivitis. Clin Ther 2003;25:931-947.
83. Whitcup SM, Bradford R, Lue J, Schiffman RM, Abelson MB. Efficacy and tolerability of ophthalmic epinastine: a randomized, double-masked, parallel-group, active- and vehicle-controlled environmental trial in patients with seasonal allergic conjunctivitis. Clin Ther 2004;26:29-34.
84. Jen A, Baroody F, De Tineo M, Haney L, Blair C, Naclerio R. As-needed use of fluticasone propionate nasal spray reduces symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol 2000;105:732-738.
85. Dykewicz MS, Kaiser HB, Nathan RA, Goode-Sellers S, Cook CK, Witham LA et al. Fluticasone propionate aqueous nasal spray improves nasal symptoms of seasonal allergic rhinitis when used as needed (prn). Ann Allergy Asthma Immunol 2003;91:44-48.
86. Fokkens WJ, Cserhati E, Dos Santos JM, Praca F, Van Zanten M, Schade A et al. Budesonide aqueous nasal spray is an effective treatment in children with perennial allergic rhinitis, with an onset of action within 12 hours. Ann Allergy Asthma Immunol 2002;89:279-284.
87. Skoner D, Rachelefsky G, Meltzer E, Chervinsky P, Morris R, Seltzer J et al. Detection of growth suppression in children during treatment with intranasal belcomethasone dipropionate. Pediatrics 2000;105:e23.
88. Allen DB, Meltzer EO, Lemanske RF Jr, Philpot EE, Faris MA, Kral KM et al. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. Allergy Asthma Proc 2002;23:407-413.
89. Schenkel EJ, Skoner DP, Bronsky EA, Miller SD, Pearlman DS, Rooklin A et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics 2000;105:E22.
90. Daley-Yates PT, Richards DH. Relationship between systemic corticosteroid exposure and growth velocity: development and validation of a pharmacokinetic/pharmacodynamic model. Clin Ther 2004;26:1905-1919.
91. Fink RS, Pierre LN, Daley-Yates PT, Richards DH, Gibson A, Honour JW. Hypothalamic-pituitary-adrenal axis function after inhaled corticosteroids: unreliability of urinary free cortisol estimation. J Clin Endocrinol Metab 2002;87:4541-4546.
92. Kim KT, Rabinovitch N, Uryniak T, Simpson B, O'Dowd L, Casty F. Effect of budesonide aqueous nasal spray on hypothalamic-pituitary-adrenal axis function in children with allergic rhinitis. Ann Allergy Asthma Immunol 2004;93:61-67.
93. Sheth KK, Cook CK, Philpot EE, Prillaman BA, Witham LA, Faris MA et al. Concurrent use of intranasal and orally inhaled fluticasone propionate does not affect hypothalamic-pituitary-adrenal-axis function. Allergy Asthma Proc 2004;25:115-120.
94. Bross-Soriano D, Hanenberg-Milver C, Schimelmitz-IDI J, Arrieta-Gomez JR, Astorga Del Toro R, Bravo-Escobar G. Effects of three nasal topical steroids in the intraocular pressure compartment. Otolaryngol Head Neck Surg 2004;130:187-191.
95. Suissa S, Baltzan M, Kremer R, Ernst P. Inhaled and nasal corticosteroid use and the risk of fracture. Am J Respir Crit Care Med 2004;169:83-88.
96. Isaksson M, Bruze M. Allergic contact dermatitis in response to budesonide reactivated by inhalation of the allergen. J Am Acad Dermatol 2002;46:880-885.
97. Bennett ML, Fountain JM, McCarty MA, Sherertz EF. Contact allergy to corticosteroids in patients using inhaled or intranasal corticosteroids for allergic rhinitis or asthma. Am J Contact Dermat 2001;12:193-196.
98. Di Lorenzo G, Pacor ML, Pellitteri ME, Morici G, Di Gregoli A, Lo Bianco C et al. Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in mono-therapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis. Clin Exp Allergy 2004;34:259-267.
99. Webb DR, Meltzer EO, Finn AF Jr, Rickard KA, Pepsin PJ, Westlund R et al. Intranasal fluticasone propionate is effective for perennial nonallergic rhinitis with or without eosinophilia. Ann Allergy Asthma Immunol 2002;88:385-390.
100. Bernstein DI, Levy AL, Hampel FC, Baidoo CA, Cook CK, Philpot EE et al. Treatment with intranasal fluticasone propionate significantly improves ocular symptoms in patients with seasonal allergic rhinitis. Clin Exp Allergy 2004;34:952-957.
101. Craig TJ, Mende C, Hughes K, Kakumanu S, Lehman EB, Chinchilli V. The effect of topical nasal fluticasone on objective sleep testing and the symptoms of rhinitis, sleep, and daytime somnolence in perennial allergic rhinitis. Allergy Asthma Proc 2003;24:53-58.
102. Ellegard EK, Hellgren M, Karlsson NG. Fluticasone propionate aqueous nasal spray in pregnancy rhinitis. Clin Otolaryngol 2001;26:394-400.
103. Davis GA, Rudy AC, Archer SM, Wermeling DP, McNamara PJ. Effect of fluticasone propionate nasal spray on bioavailability of intranasal hydromorphone hydrochloride in patients with allergic rhinitis. Pharmacotherapy 2004;24:26-32.
104. Gawchik S, Goldstein S, Prenner B, John A. Relief of cough and nasal symptoms associated with allergic rhinitis by mometasone furoate nasal spray. Ann Allergy Asthma Immunol 2003;90:416-421.
105. Potter PC, Van Niekerk CH, Schoeman HS. Effects of triamcinolone on quality of life in patients with persistent allergic rhinitis. Ann Allergy Asthma Immunol 2003;91:368-374.
106. McFadden EA, Gungor A, Ng B, Mamikoglu B, Moinuddin R, Corey J. Loratadine/pseudoephedrine for nasal symptoms in seasonal allergic rhinitis: a double-blind, placebo-controlled study. Ear Nose Throat J 2000;79:254, 257-258, 260 passim.
107. Nayak AS, Banov C, Corren J, Feinstein BK, Floreani A, Friedman BF et al. Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma. Cochrane Database Syst Rev 2000;2:417-424.
108. Philip G, Malmstrom K, Hampel FC, Weinstein SF, Laforce CF, Ratner PH et al. Montelukast for treating seasonal allergic rhinitis: a randomized, doubleblind, placebo-controlled trial performed in the spring. Clin Exp Allergy 2002;32:1020-1028.
109. Van Adelsberg J, Philip G, Pedinoff AJ, Meltzer EO, Ratner PH, Menten J et al. Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period. Allergy 2003;58:1268-1276.
110. Van Adelsberg J, Philip G, Laforce CF, Weinstein SF, Menten J, Malice MP et al. Randomized controlled trial evaluating the clinical benefit of montelukast for treating spring seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2003;90:214-222.
111. Chervinsky P, Philip G, Malice MP, Bardelas J, Nayak A, Marchal JL et al. Montelukast for treating fall allergic rhinitis: effect of pollen exposure in 3 studies. Ann Allergy Asthma Immunol 2004;92:367-373.
112. Meltzer EO, Malmstrom K, Lu S, Prenner BM, Wei LX, Weinstein SF et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial. J Allergy Clin Immunol 2000;105:917-922.
113. Philip G, Nayak AS, Berger WE, Leynadier F, Vrijens F, Dass SB et al. The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis. Curr Med Res Opin 2004;20:1549-1558.
114. Kurowski M, Kuna P, Gorski P. Montelukast plus cetirizine in the prophylactic treatment of seasonal allergic rhinitis: influence on clinical symptoms and nasal allergic inflammation. Allergy 2004;59:280-288.
115. Pullerits T, Praks L, Ristioja V, Lotvall J. Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 2002;109:949-955.
116. Wilson AM, O'Byrne PM, Parameswaran K. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Am J Med 2004;116:338-344.
117. Simons FE, Johnston L, Gu X, Simons KJ. Suppression of the early and late cutaneous allergic responses using fexofenadine and montelukast. Ann Allergy Asthma Immunol 2001;86:44-50.
118. Hill SL III, Krouse JH. The effects of montelukast on intradermal wheal and flare. Otolaryngol Head Neck Surg 2003;129:199-203.
119. Casale TB, Condemi J, Laforce C, Nayak A, Rowe M, Watrous M et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. Jama 2001;286:2956-2967.
120. Adelroth E, Rak S, Haahtela T, Aasand G, Rosenhall L, Zetterstrom O et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000;106:253-259.
121. Chervinsky P, Casale T, Townley R, Tripathy I, Hedgecock S, Fowler-Taylor A et al. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol 2003;91:160-167.
122. Nayak A, Casale T, Miller SD, Condemi J, McAlary M, Fowler-Taylor A et al. Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis. Allergy Asthma Proc 2003;24:323-329.
123. Berger W, Gupta N, McAlary M, Fowler-Taylor A. Evaluation of longterm safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. Ann Allergy Asthma Immunol 2003;91:182-188.
124. Vignola AM, Humbert M, Bousquet J, Boulet LP, Hedgecock S, Blogg M et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004;59:709-717.
125. Plewako H, Arvidsson M, Petruson K, Oancea I, Holmberg K, Adelroth E et al. The effect of omalizumab on nasal allergic inflammation. J Allergy Clin Immunol 2002;110:68-71.
126. Bez C, Schubert R, Kopp M, Ersfeld Y, Rosewich M, Kuehr J et al. Effect of anti-immunoglobulin E on nasal inflammation in patients with seasonal allergic rhinoconjunctivitis. Clin Exp Allergy 2004;34:1079-1085.
127. Beck LA, Marcotte GV, MacGlashan D, Togias A, Saini S. Omalizumab-induced reductions in mast cell Fce psilon RI expression and function. J Allergy Clin Immunol 2004;114:527-530.
128. Hanf G, Noga O, O'Connor A, Kunkel G. Omalizumab inhibits allergen challenge-induced nasal response. Eur Respir J 2004;23:414-418.
129. Lin H, Boesel KM, Griffith DT, Prussin C, Foster B, Romero FA et al. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils. J Allergy Clin Immunol 2004;113:297-302.
130. Prussin C, Griffith DT, Boesel KM, Lin H, Foster B, Casale TB. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol 2003;112:1147-1154.
131. Kuehr J, Brauburger J, Zielen S, Schauer U, Kamin W, Von Berg A et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 2002;109:274-280.
132. Rolinck-Werninghaus C, Hamelmann E, Keil T, Kulig M, Koetz K, Gerstner B et al. The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children. Allergy 2004;59:973-979.
133. Fokkens WJ, Scadding GK. Perennial rhinitis in the under 4s: a difficult problem to treat safely and effectively? A comparison of intranasal fluticasone propionate and ketotifen in the treatment of 2-4-year-old children with perennial rhinitis. Pediatr Allergy Immunol 2004;15:261-266.